# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and maintains $125 price target.
NYSE experiences trading halts Monday due to a technical issue. Stocks like Berkshire Hathaway and Chipotle are impacted.
Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis i...
Goldman Sachs analyst David Roman initiates coverage on Abbott Laboratories (NYSE:ABT) with a Buy rating and announces Price...